Krystal Biotech, Inc.

Total Valuation

Krystal Biotech, Inc. carries a market capitalization of 8.90B, placing it among publicly traded companies globally. Its enterprise value stands at 6.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Krystal Biotech, Inc. currently has 29.44M shares outstanding.

Valuation Ratios

Krystal Biotech, Inc. trades at a trailing price-to-earnings ratio of 33.36. The price-to-sales ratio is 17.99, and the price-to-book ratio stands at 93.73.

Enterprise Valuation

On an enterprise value basis, Krystal Biotech, Inc. trades at an EV/EBITDA multiple of 36.12 and an EV/FCF ratio of 25.43. The EV/Sales ratio of 16.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 37.46 provides insight into valuation relative to core operating earnings.

Financial Position

Krystal Biotech, Inc. maintains a current ratio of 9.46, meaning it holds 9.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Taxes

Over the trailing twelve months, Krystal Biotech, Inc. has paid -17.71M in income taxes, reflecting an effective tax rate of 27.02.

Stock Price Statistics

Krystal Biotech, Inc.'s stock has gained approximately 130.55534% over the past 52 weeks. The 50-day moving average sits at 279.07, while the 200-day moving average is 233.99.

Income Statement

Over the trailing twelve months, Krystal Biotech, Inc. generated 417.30M in revenue and converted that into 225.03M in net income, yielding earnings per share of 7.48. EBITDA reached 185.28M, while operating income came in at 178.64M.

Balance Sheet

Krystal Biotech, Inc. holds 823.41M in cash and equivalents against 9.11M in total debt, resulting in a net debt position of -501.31M. Total book value stands at 80.10M, with working capital of 911.94M providing operational flexibility.

Cash Flow

Krystal Biotech, Inc. produced 250.28M in operating cash flow over the past twelve months. After subtracting -12.89M in capital expenditures, free cash flow totaled 237.38M - equivalent to 8.17 per share.

Margins

Krystal Biotech, Inc. operates with a gross margin of 94.17, reflecting its pricing power and cost economics. The operating margin of 42.81 and net profit margin of 53.92 provide insight into operational efficiency.

Dividends & Yields

Scores

Krystal Biotech, Inc. posts an Altman Z-Score of 39.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.